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NOTE 
Protecting Minors with Substance Use Disorders: A Closer Look at the 
Relationship of Confidentiality with Treatment Options 
Katherine Slisz* 
INTRODUCTION 
 Cindy, fourteen, sits in the substance use disorder (SUD) treatment 
provider’s office after having traveled there from her parents’ middle-class 
suburban home. The provider asks Cindy if she would like to sign the information 
release form or keep her treatment information confidential. She thinks for a 
moment about her parents, whom she believes would be disappointed to learn of her 
SUD. She does not want to upset her parents or face their discipline, so she refuses 
to sign the paperwork that would allow the release of her information. This 
hypothetical situation provides one example of the lack of understanding many 
minors possess when it comes to confidentiality concerning SUD treatment. 
 SUD is classified as a mental health disorder that “occur[s] when the 
recurrent use of alcohol and/or substances causes clinically and functionally 
significant impairment, such as health problems, disability, and failure to meet 
major responsibilities at work, school, or home.”1 An SUD diagnosis is made based 
on evidence of impaired control, social impairment, risky use, and pharmacological 
criteria.2 In 2014, of United States adolescents ages 12 to 17, an estimated 5%, or 
about 1.3 million adolescents, had SUD.3 The 1.3 million adolescents suffering from 
this challenging disorder present vulnerabilities that require caution, care, and 
concern in treatment. 
 Adolescents may find a number of treatments for SUD helpful based on the 
individual’s situation.4 Some adolescents receive treatments where providers work 
directly with the adolescent to help them cope with their environment and other 
providers take group therapy approaches, like family-based treatment.5 Treatment 
providers work to allow adolescents to better understand their interactions with 
 
*  Indiana University Maurer School of Law, J.D. 2020; Executive Editor, Indiana Journal of Law 
& Social Equality, Volume 8. 
1  Mental Health and Substance Use Disorder, SUBSTANCE ABUSE & MENTAL HEALTH SERVS. 
ADMIN., https://www.samhsa.gov/disorders/substance-use (last updated Apr. 13, 2019).  
2  AM. PSYCHIATRIC ASS’N, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS (5th ed. 
2013). 
3  Age- and Gender-Based Populations, SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN. (Jan. 
17, 2018), https://www.samhsa.gov/specific-populations/age-gender-based 
[https://web.archive.org/web/20190306023430/https://www.samhsa.gov/specific-populations/age-
gender-based]. 
4  NAT’L INST. ON DRUG ABUSE, PRINCIPLES OF ADOLESCENT SUBSTANCE USE DISORDER TREATMENT 
23 (2014). 
5  Id. at 23–25. 
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their external environment and how they cope with their desire for substances in 
the future.6 Treatment providers also strive to build a system of social support 
around adolescents with SUD.7 
Confidentiality requirements for substance use treatment were codified in 
1975 in 42 CFR Part 2 (Part 2) as part of the Drug Abuse Office and Treatment 
Act.8 Within Part 2 of the regulation, 42 CFR 2.14 (Section 2.14) provides minors 
similar consent rights as adults, meaning that minors must give consent for their 
information to be released to outside parties.9 Individuals having the capacity to 
consent to treatment is always assumed under the regulation.10 The regulation 
depends on the assumption that minors are more likely to seek treatment when 
their SUD treatment provider can promise confidentiality.11 To achieve Section 
2.14’s purpose, treatment providers must consider the harm that maintaining 
confidentiality will do to the parent-child relationship and the child themselves.12 
An examination of SUD’s psychological effect on adolescents is necessary to 
understand how Section 2.14 may work in conjunction with minors’ desire for 
confidentiality. While confidentiality mandated under Section 2.14 provides 
important benefits for adolescents seeking privacy for SUD treatment, there are 
many treatment reasons why providers should be reporting care for serious SUD to 
parents absent extraordinary circumstances. Therefore, this Note argues that, 
based on Section 2.14(c), providers should have more guidance both to supply 
adolescents with adequate information about family-based treatment and to protect 
the well-being of vulnerable adolescents by sharing more information with parents 
and guardians. 
Section I provides background surrounding the regulation Part 2, along with 
its purpose. Section II discusses minors’ interactions with the health care system, 
how substance use affects minors’ brains, and alternative treatments for SUD. 
Section III explores why some minors with SUD lack maturity to make the decision 
of whether or not to maintain confidentiality, including the importance of medical 
informed consent, both medical and legal capacity, traditional legal standards, and 
case law. Section IV then examines how these understandings may conflict with or 
change the meaning of Section 2.14(c)’s provisions. Finally, Section V proposes a 
solution to Section 2.14(c)’s vagueness: a process for providers and psychologists to 
 
6  Id. at 21, 23, 25. 
7  Id. at 17–23. 
8  Part 2—Confidentiality of Alcohol and Drug Abuse Patient Records, 40 Fed. Reg. 27,802 (July 1, 
1975) (to be codified at 42 C.F.R. pt. 2). See Drug Abuse Office and Treatment Act of 1972, Pub. 
L. No. 92-255, 86 Stat. 65 (1972); Comprehensive Alcohol Use and Alcoholism Prevention, 
Treatment, and Rehabilitative Act of 1970, Pub. L. No. 91-616, 84 Stat. 1848 (1970) (providing 
legislative authority to enact the 1975 regulation). 
9  See 42 C.F.R. § 2.14(a) ( 2018). 
10  Id.  
11  See infra note 46 and accompanying text. 
12  See Part 2—Confidentiality of Alcohol and Drug Abuse Patient Records, 40 Fed. Reg. 27,802. 
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determine if minors with SUD have been fully informed of the importance of social 
support and have the maturity to consent to treatment. 
I. BACKGROUND AND PURPOSE OF 42 CFR PART 2 
Federal privacy regulations exist in the current healthcare system to protect 
individuals from unwanted information sharing.13 Part 2 was created to allow 
individuals with SUD to seek treatment with confidentiality, therefore decreasing 
stigmatization.14 As substance use was on the rise in the 1960s, law enforcement 
attempted to control illegal substance use through punitive measures; however, by 
the late 60s and early 70s, they realized this punitive method was ineffective.15 
Furthermore, fear of discrimination deterred people from entering substance use 
treatment programs.16 To move away from punishment and towards treatment, the 
federal government first enacted the Comprehensive Alcohol Use and Alcoholism 
Prevention, Treatment and Rehabilitation Act of 1970.17 This Act encouraged people 
to view SUD as a medical problem, rather than a moral problem.18 The government 
next enacted the Substance Use Office and Treatment Act of 1972, aimed at 
supporting treatment and rehabilitation programs.19  
Title 42 Part 2 was then enacted in 1975 pursuant to authority given in the 
previous Acts.20 A joint action of the Special Action Office for Substance Use 
Prevention and the Department of Health, Education, and Welfare (later renamed 
The Department of Health and Human Services (HHS)) enacted Part 2 due to a 
transfer of authority from the Director of the Special Action Office for Substance 
Use Prevention, to the Secretary of the Department of Health, Education, and 
 
13  42 CFR Part 2 Confidentiality of Substance Use Disorder Patient Records, SUBSTANCE ABUSE & 
MENTAL HEALTH SERVS. ADMIN., https://www.samhsa.gov/health-information-technology/laws-
regulations-guidelines 
[https://web.archive.org/web/20190109052630/https://www.samhsa.gov/health-information-
technology/laws-regulations-guidelines] (last updated Oct. 12, 2018). 
14  See Part 2—Confidentiality of Alcohol and Drug Abuse Patient Records, 40 Fed. Reg. 27,802. 
15  David F. Musto, Drug Abuse Research in Historical Perspective, in INST. MED., PATHWAYS OF 
ADDICTION: OPPORTUNITIES IN DRUG ABUSE RESEARCH app. B, at 284, 290 (1996). 
16  Mitchell Berger, Confidentiality of Substance Use Disorder Patient Records Final Rule (42 CFR 
Part 2), RESIDENTIAL SUBSTANCE ABUSE TREATMENT–TRAINING & TECHNICAL ASSISTANCE 1, 3 
(2017), http://www.rsat-tta.com/Files/Confidentiality-Rules-and-Regulations_BERGER-(1). 
17  Id. 
18  History of NIAAA, NAT’L INST. ALCOHOL ABUSE & ALCOHOLISM, https://www.niaaa.nih.gov/our-
work/history-niaaa (last visited Oct. 1, 2018). 
19  See Berger, supra note 16; Richard Nixon, Statement About the Substance Use Office and 
Treatment Act of 1972, AM. PRESIDENCY PROJECT (Mar. 21, 1972), 
https://www.presidency.ucsb.edu/node/255218 (including information about the “balanced attack” 
to prosecute the “heroin pusher” in order to protect the “pusher’s victim”). 
20  Drug Abuse Office and Treatment Act of 1972, Pub. L. No. 92-255, 86 Stat. 65 (1972); 
Comprehensive Alcohol Use and Alcoholism Prevention, Treatment, and Rehabilitative Act of 
1970, Pub. L. No. 91-616, 84 Stat. 1848 (1970) (providing legislative authority to enact the 1975 
regulation). 
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Welfare.21 Part 2 governs confidentiality in federally-assisted SUD treatment 
programs.22 In most circumstances, the regulation requires that providers obtain 
patients’ consent before releasing information to others.23 This regulation furthers 
the purpose of protecting those with SUD from stigmatization.24 
The 1975 version of Part 2 was the first legislation to give minors 
confidentiality rights in SUD treatment.25 Its purpose was to allow minors 
confidentiality without interfering in parent-child relationships, and to be 
consistent with local policy and reinforce the importance that states placed on 
family relationships.26 The rule states disclosures may be made if in the patient’s 
best interest,27 but it does not explicitly define capacity to give consent to 
confidentiality and how to assess it. The regulation was written so treatment 
providers would not be torn between violating Part 2 and acting in the minor 
patient’s best interests: “[O]ther rule(s) could subject clinicians to an intolerable 
choice between violating the provisions of this part . . . , or failing to take action to 
avoid a preventable tragedy involving a minor. . . . The statutes . . . should not be 
read as requiring such a choice.”28 
Part 2 was last substantially updated in 1987 with respect to payment 
information and criminal justice system referrals.29 With the widespread 
advancement of technology since 1987, the regulation desperately needed updates, 
including the integration of information sharing with electronic health records 
(EHRs)30 which risk breaching confidentiality and could deter fearful patients from 
seeking SUD treatment due to the stigma.31 The former director of the Center for 
Substance Use Treatment at Substance Abuse and Mental Health Services 
Administration (SAMHSA), Dr. H. Westley Clark, was responsible for interpreting 
the previous version of Part 2.32 Clark believed that some EHR sellers who 
 
21  Confidentiality of Alcohol and Drug Abuse Patient Records, 40 Fed. Reg. 20,522 (proposed May 9, 
1975) (to be codified at 42 C.F.R. pt. 2); Part 2—Confidentiality of Alcohol and Drug Abuse 
Patient Records, 40 Fed. Reg. 27,802. See also Comprehensive Alcohol Use and Alcoholism 
Prevention, Treatment, and Rehabilitative Act of 1970, Pub. L. No. 93-282, 88 Stat. 138. 
22  42 CFR Part 2 Confidentiality of Substance Use Disorder Patient Records, supra note 13. 
23  Id. 
24  See id. 
25  See Part 2—Confidentiality of Alcohol and Drug Abuse Patient Records, 40 Fed. Reg. 27,802 
(July 1, 1975) (to be codified at 42 C.F.R. pt. 2). 
26  Id. 
27  Id. 
28  Id. 
29  42 CFR Part 2 Confidentiality of Substance Use Disorder Patient Records, supra note 13; see also 
Confidentiality of Alcohol and Drug Abuse Patient Records, 52 Fed. Reg. 21,796 (June 9, 1987) 
(to be codified at 42 C.F.R. pt. 2) (changing “Minor patients.” from Section 2.15 to 2.14 with 
minimal changes to the text). 
30  Alison Knopf, Upcoming Rule on 42 CFR Part 2 Could Harm SUD Patients, 29 ALCOHOLISM & 
DRUG ABUSE WEEKLY 3, 4 (2017). 
31  Id. 
32  Id. 
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previously struggled with Part 2 compliance simply wished to update the regulation 
for business interests, particularly because of the opioid epidemic and the nation’s 
concern surrounding substance use. 33 Based on this national issues some EHR 
system vendors hoped that their products would see increased sales.34 Around 2010, 
prior to the current updates, SAMHSA worked to help health providers integrate 
technology into their Part 2 compliance efforts.35 Despite these efforts, stakeholders 
were still requesting regulatory updates.36  
In February of 2016, HHS published new proposed rule changes to Part 2.37 
SAMHSA published the final rule, and in February 2017, the rule went into effect.38 
The regulation was renamed from “Confidentiality of Alcohol and Substance Use 
Patient Records” to ‘‘Confidentiality of Substance Use Disorder Patient Records.’’39 
Section 2.14 currently states, “If a minor patient acting alone has the legal capacity 
under the applicable state law to apply for and obtain substance use disorder 
treatment, any written consent for disclosure . . . may be given only by the minor 
patient.”40 The updates to Part 2 should ultimately help treatment providers 
incorporate health care delivery systems, including electronic information sharing.41  
Changes to Part 2 will ultimately allow SUD treatment information to be 
shared with others in the same healthcare system with consent, while leaving in 
place existing confidentiality provisions for all communications outside the 
healthcare system.42 Compared to different health information privacy laws like the 
Health Insurance Portability and Accountability Act (HIPAA), Part 2 contains the 
strictest health privacy standards because disclosure of SUD may subject patients 
to discrimination or legal consequences.43 
The purpose of these updates applies to minors as well. One of the issues 
with Section 2.14 is that although there were no changes to this “Minor patients” 
section, comments were made with “specific suggestions or requested 
 
33  Id. 
34  Id. 
35  Confidentiality of Substance Use Disorder Patient Records, 82 Fed. Reg. 6052 (Jan. 18, 2017) (to 
be codified at 42 C.F.R. pt. 2). 
36  Id. 
37  Id. 
38  Id. 
39  Id. 
40  42 C.F.R. § 2.14(a) (2018). 
41  Id. See Confidentiality of Substance Use Disorder Patient Records, 81 Fed. Reg. 6988 (proposed 
Feb. 9, 2016) (to be codified at 42 C.F.R. pt. 2).  
42  Setting the Record Straight: ASAM’s Position in 42 CFR Part 2, AM. SOC’Y ADDICTION MED. (Aug. 
11, 2017), https://www.asam.org/advocacy/issues/confidentiality-(42-cfr-part-2). 
43  HHS Publishes Final Rule on Confidentiality of Substance Use Disorder Patient Records, HIPAA 
J. (Jan. 3, 2018), https://www.hipaajournal.com/final-rule-confidentiality-of-substance-use-
disorder-patient-records.  
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clarification.”44 Commenters ranged from health insurance management 
associations to behavioral health management organizations.45 
II. PSYCHOLOGICAL EFFECTS OF MEDICAL CARE FOR MINORS 
A. Minors’ Desire for Confidentiality in Health Care 
Many minors prioritize confidentiality and autonomy in their medical 
decision making. One study found that one-fourth of participating adolescents 
would not seek general health care if they believed that their parents, friends, or 
teachers could find out.46 These findings confirmed that a lack of confidentiality 
may create a barrier to health care.47 A later study noted that 76% of teens wanted 
to obtain health care without parental knowledge,48 and 8% of teens wanted health 
care in the previous twelve months, but did not seek it, fearing that their parents 
would be notified.49 However, confidentiality may not be enough; 7% of teens who 
believed their provider would keep information confidential still did not seek 
healthcare out of fear that their parents would find out.50 Therefore, although 
minors desire confidentiality and it is an important predictor of whether adolescents 
will seek health care, its presence does not guarantee that adolescents will seek 
health care.51 
B. Current Substance Use Trends Among Minors 
SUD affects adolescents of all populations. When compared to Caucasian 
adolescents, African-American students reported less substance use, and Hispanic 
 
44  Confidentiality of Substance Use Disorder Patient Records, 82 Fed. Reg. 6105 (Jan. 18, 2017) (to 
be codified at 42 C.F.R. pt. 2). 
45  Rhode Island Quality Health Institute, Comment Letter on Proposed Rule to Confidentiality of 
Substance Use Disorder Patient Records (Apr. 11, 2016), 
https://www.regulations.gov/document?D=HHS-OS-2016-0005-0222; Beacon Health Options, 
Comment Letter on Proposed Rule to Confidentiality of Substance Use Disorder Patient Records 
(Apr. 11, 2016), https://www.regulations.gov/document?D=HHS-OS-2016-0005-0292; Association 
for Behavioral Health and Wellness, Comment Letter on Proposed Rule to Confidentiality of 
Substance Use Disorder Patient Records (Feb. 17, 2017), 
https://www.regulations.gov/document?D=HHS-OS-2016-0005-0402. 
46  Tina L. Cheng, Judith A. Savageau, Ann L. Sattler & Thomas G. DeWitt, Confidentiality in 
Health Care: A Survey of Knowledge, Perceptions, and Attitudes Among High School Students, 
269 JAMA 1404, 1406 (1993) (study conducted by Cheng et al.). 
47  Id. 
48  Jeannie S. Thrall, Lois McCloskey, Susan L. Ettner, Edward Rothman, Joan E. Tighe & S. Jean 
Emans, Confidentiality and Adolescents’ Use of Providers for Health Information and for Pelvic 
Examinations, 154 ARCHIVES PEDIATRICS & ADOLESCENT MED. 885, 886 (2000) (study conducted 
by Thrall et al.). 
49  Id. at 888. 
50  Id. at 886, 889 (finding 45% believed their regular provider could keep health services 
confidential). 
51  Id. 
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adolescents reported more substance use.52 Maternal and paternal knowledge of 
adolescent substance use led to a lower likelihood that adolescents will use 
substances.53 Open communication between parents and adolescents about alcohol 
use and its effects was a significant predictor for lower levels of drinking.54 
Furthermore, parent permissiveness of substance use, or parental substance use 
itself, increased the likelihood that adolescents would engage in substance use.55 
Studies confirmed that alcohol and marijuana use were higher in the middle- to 
upper-class communities of adolescents, possibly because these adolescents have the 
funds to obtain substances and fake identification.56 
Reducing risk factors and enhancing protective factors have also been linked 
to protecting adolescents from SUD.57 Risk factors include external elements like 
permissive parenting, bullying, and living in a community with high drug 
tolerance.58 Protective factors look to combat these risks by giving adolescents a 
strong bond with parents, spending time around positive role models, and 
promoting the belief that substance use can be dangerous.59 Environmental factors 
are prevalent throughout research because, when compared to genetic factors, 
environmental factors may be more easily addressed. 
On the whole, substance use among minors is currently on the decline.60 
Adolescents’ use of illicit substances, other than marijuana, has decreased, this 
overall includes a decrease in prescription opioid use, and researchers have also 
identified a decrease in binge alcohol use.61 However, harmful substances are still a 
problem among teens, with alcohol and tobacco as the most frequently used 
substances and marijuana a close third.62 Teens are more accepting of marijuana; 
 
52  Jing Wang, Bruce G. Simons-Morton, Tilda Farhart & Jeremy W. Luk, Socio-Demographic 
Variability in Adolescent Substance Use: Mediation by Parents and Peer, PUBMED CENT. 1, 6 
(2011) (study conducted by Wang et al.). 
53  Id. at 10. 
54  Does Socioeconomic Advantage Lessen the Risk of Adolescent Substance Use?, HAZELDEN BETTY 
FORD FOUND., https://www.hazeldenbettyford.org/education/bcr/addiction-
research/socioeconomic-advantage-edt-818 (last visited Nov. 17, 2018) (findings based on a 2016 
study from Hausheer, Doumas, Esp & Cuffee). 
55  Id. (findings based on a 2017 study from Cambron, Kosterman, Catalano, Guttmannova & 
Hawkins). 
56  Id. (study conducted by Luthar and Milliren et al.). 
57  Why Do Teens Use Drugs?, GET SMART ABOUT DRUGS (Aug. 14, 2018), 
https://www.getsmartaboutdrugs.gov/family/why-do-teens-use-drugs. 
58  Id. 
59  Id. 
60  See Monitoring the Future Survey: High School and Youth Trends, NAT’L INST. ON DRUG USE 
(Dec. 2019), https://www.drugabuse.gov/publications/drugfacts/monitoring-future-survey-high-
school-youth-trends. 
61  Id. (conducting a study of 8th, 10th, and 12th graders). 
62  What Drugs are Most Frequently Used by Adolescents?, NAT’L INST. ON DRUG USE (Jan. 2014), 
https://www.drugabuse.gov/publications/principles-adolescent-substance-use-disorder-treatment-
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only 29% of twelfth graders believe that “regular marijuana use poses a great risk,” 
and daily marijuana use among twelfth graders is currently higher than cigarette 
use.63 The National Institute for Substance Use for Teens noted that twelfth 
graders’ use of marijuana has risen from 5.1% in 2007 to 5.9% in 2017.64  
Additionally, adolescents’ opioid use is increasing. According to data from a 
2002–2006 Monitoring the Future survey, “1 out of 8 high school seniors reported 
having used prescription opioids nonmedically [and] 7 out of 10 nonmedical users 
reported combining prescription opioids with at least one other substance in the 
past year.”65 According to a study by Dr. Marcel Casavant, 30% of calls to U.S. 
poison control centers for children ingesting prescription opioids were for teenagers 
who had taken the opioids intentionally to get high or for self-harm.66 Of the 175 
children who died from ingesting opioids, 55% were teenagers; however, the rate of 
calls per 100,000 adolescents decreased from 80% in 2009 to 50% by 2015.67 The 
excessive use of substances by adolescents may create larger repercussions on their 
mental states. 
C. Effects of Substance Use on Minors 
Adolescents’ substance use presents physical and psychological health issues. 
A substantial amount of brain growth happens during the adolescent and teen 
years. The prefrontal cortex, which makes decisions, continues to develop until the 
mid-20s.68 The prefrontal cortex regulates decision-making, reasoning, personality 
expression, and social behavior.69 The development in the prefrontal cortex, or 
“frontalization,” may underlie adolescents’ growing ability to think about how they 
are perceived by others, leading to increased feelings that they are constantly being 




63  Id. See Teens Mix Prescription Opioids with Other Substances, NAT’L INST. ON SUBSTANCE USE 
(Apr. 2013), https://www.drugabuse.gov/related-topics/trends-statistics/infographics/teens-mix-
prescription-opioids-other-substances (finding most common combination of substances among 
youths in a 2002–2006 study was marijuana and alcohol (58.5% and 52.1%)). 
64  Shamard Charles, Marijuana Worse for Teen Brains than Alcohol, Study Finds, NBC NEWS (Oct. 
3, 2018), https://www.nbcnews.com/health/kids-health/marijuana-may-be-worse-teen-brains-
alcohol-study-finds-n916296. 
65  Teens Mix Prescription Opioids with Other Substances, supra note 63. 
66  Amy Norton, Fewer U.S. Kids Overdosing on Opioids, WEBMD (Mar. 20, 2017), 
https://www.webmd.com/mental-health/addiction/news/20170320/fewer-us-kids-overdosing-on-
opioids. 
67  Id. (“This study can’t show why.”). 
68  How Drugs Alter Brain Development and Affect Teens, GET SMART ABOUT DRUGS (Feb. 7, 2020), 
https://www.getsmartaboutdrugs.gov/consequences/how-drugs-alter-brain-development-and-
affect-teens. 
69  Erika Packard, That Teenage Feeling, 38 AM. PSYCHOL. ASS’N  20, 21 (Apr. 2007), 
https://www.apa.org/monitor/apr07/teenage.aspx. 
70  Id. 
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reasoning increases, including the ability to make inferences about others’ thoughts 
and feelings, so does social anxiety, which may make adolescents feel more 
vulnerable and self-conscious.71 SUD may affect this brain development and 
psychological growth. 
During brain maturation, the frontal lobe, associated with “planning, 
inhibition, emotional regulation, and integration of novel stimuli,” increases in 
efficiency.72 The brain’s plasticity permits large learning capacity, which may be 
affected by alcohol and substance use.73 Exposure to harmful substances during a 
period of key brain development “interrupt[s] the natural course of brain 
maturation.”74 Substance use in pre-teenagers has extraordinary risks because it 
increases the likelihood that this use will progress to more dangerous substances, in 
turn affecting the adolescent’s “physical, physiologic, neurologic, and emotional 
development.”75  
Heavy drinking in teen years disturbs the working memory, including 
“attention, information retrieval, . . . visuospatial functioning,” information 
processing speed, and executive functioning.76 In a study by Brown et al., adolescent 
drinkers recalled 10% less verbal and nonverbal information compared to non-
drinkers.77 Even after the minor stops drinking, it may be weeks or months until 
the brain is back to its optimal capacity.78 
Marijuana use causes similar neurological damage among adolescents. Many 
believe that marijuana is less harmful than alcohol; however, many recent studies 
confirm that it may be more harmful.79 Adolescents who use marijuana have “a less 
efficient pattern of activation compared to non-users on working memory, verbal 
learning, and cognitive control tasks.”80 Further, Cass et al. found that early 
 
71  Id. Isabelle Rosso, PhD, works in Harvard University's McLean Hospital Cognitive 
Neuroimaging and Neuropsychology Laboratory. Id. 
72  L.M. Squeglia, J. Jacobus & S.F. Tapert, The Influence of Substance Use on Adolescent Brain 
Development, 40 CLINICAL EEG & NEUROSCIENCE 31, 32 (2010) (“In a study comparing prefrontal 
cortex volumes of adolescent heavy drinkers to non-drinkers and marijuana and alcohol users, 
prefrontal volumes were smaller in heavy drinkers relative to controls.”). 
73  Richard C. Bodlt, Symposium, Adolescent Decision Making: Legal Issues with Respect to 
Treatment for Substance Misuse and Mental Illness, 15 J. HEALTH CARE L. & POL’Y 75, 87 (2012). 
74  Squeglia et al., supra note 72, at 2.  
75  John W. Kulig & The Comm. on Substance Abuse, Tobacco, Alcohol, and Other Drugs: The Role 
of the Pediatrician in Prevention and Management of Substance Abuse, 115 J. AM. ACAD. 
PEDIATRICS 816, 820 (2005). 
76  Sunita Bava & Susan F. Tapert, Adolescent Brain Development and the Risk for Alcohol and 
Other Drug Problems, 20 NEUROPSYCHOLOGY REV. 398, 405 (2010). 
77  Squeglia et al., supra note 72, at 32 (continuing verbal and nonverbal problems even three weeks 
after abstinence). 
78  How Drugs Alter Brain Development and Affect Teens, supra note 67. 
79  Charles, supra note 64 (according to a study published in the American Journal of Psychiatry, 
marijuana has a more damaging long-term effect on the cognitive abilities of teenagers than 
alcohol). 
80  Bava & Tapert, supra note 76. 
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adolescent brain receptors repeatedly exposed to cannabinoids ultimately 
experienced a slowed prefrontal cortex.81 These deficiencies linger, and after four 
weeks of abstinence, adolescents who regularly smoked continued to poorly perform 
on tests of working memory, learning, and cognitive flexibility, along with other 
performance tests.82 These same adolescents with SUD have shown their capacity to 
make good decisions by seeking treatment, but other decisions might be challenging 
in different ways because of the adolescent’s immaturity compounded by the 
cognitive deficits of substance use.83 The new decision-making hurdles that 
adolescents might face also surround social and relational fears, showing the need 
to destigmatize SUD.84 Providers must fully evaluate both the nature and extent of 
the substance use in order to offer counseling that is appropriate, or know when to 
make referrals.85  
D. Treatment Alternatives for SUD 
There are numerous types of treatments that may be used for adolescents 
with SUD, and not all treatment options will benefit each adolescent in the same 
way.86 There are behavioral approaches that work to “modify [adolescents’] 
attitudes and behaviors related to drug abuse” and assist with other communication 
issues or environmental reasons an adolescent would use substances.87 Group 
therapy also allows adolescents to connect with and receive support from their 
peers.88 Family-based treatments may be more effective than individual and group 
treatment approaches, allowing parents and family into the process of the SUD 
recovery to both communicate and work on conflict resolution.89  
SAMHSA notes the importance of social support and building meaningful 
relationships within the community in SUD recovery.90 Social support may vary 
among adolescents who may have different primary relationships in their lives; 
some may confide in peers, while others may involve parents or a trusted adult.91 
Upon entering SUD treatment, providers must know the adolescent’s relational 
 
81  Study: Regularly Using Marijuana as a Teen Slows Brain Development, GET SMART ABOUT 
DRUGS (Oct. 13, 2017), https://www.getsmartaboutsubstances.gov/news-
statistics/2017/04/14/study-regularly-using-marijuana-teen-slows-brain-development. 
82  Squeglia et al., supra note 72, at 3. 
83  See supra Part II.C. 
84  See Packard, supra note 69. 
85  Id. 
86  NAT’L INST. ON DRUG ABUSE, PRINCIPLES OF ADOLESCENT SUBSTANCE USE DISORDER TREATMENT 
23 (2014). 
87  Id. 
88  Id.  
89  See id. at 17. 
90  Recovery and Recovery Support, SUBSTANCE ABUSE AND MENTAL HEALTH ADMIN. (Oct. 2018), 
https://www.samhsa.gov/recovery. 
91  See id. 
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network and their strengths and weaknesses.92 Providers must understand the 
culture of the community that they serve, including the community’s values and 
traditions, in order to create and advise effective treatment plans.93 
Adolescents undergoing SUD treatment must be fully informed of the various 
types of treatment. Further, adolescents should be informed of the treatment 
options that may no longer be available to them if they chose to make their SUD 
treatment confidential. 
III. STANDARDS FOR CAPACITY AND UNDERSTANDING WITHIN MEDICAL DECISIONS 
Adolescents dealing with SUD have the capacity to seek treatment.94 There is 
not an issue with allowing minors to access treatment; however, the problem with 
current treatment regulations stems from the fact that most of these adolescents 
may have trouble making decisions about treatment options because they may 
overestimate how SUD stigma can harm their relationships and underestimate the 
importance of support networks.95 Immaturity and increased vulnerability make 
these issues more complex.96 Adolescents have an appraisal system tasked with 
weighing the positives and negatives of decisions.97 The appraisal system “over-
emphasizes the positive aspects of a choice, and de-emphasizes the negative aspects 
of a choice.”98 Adolescents who are more likely to have an SUD have a hyper-
rational brain,99 meaning the adolescents place more weight on the benefit than the 
risk.100 Therefore, adolescents who have a heightened hyper-rational brain may not 
be able to appropriately weigh the “risk” of telling their parent against the 
benefit.101 Moreover, the substance use, depending on nature and type, may have 
further damaged the adolescent’s ability to fully consider the decision of 
confidentiality. 
Adolescents have made the good decision to seek treatment; however, based 
on the nature of SUD, further assistance may be necessary to achieve broader 
understanding of the role of support and the need to disclose their SUD. These 
adolescents must be provided adequate information, based on their maturity, in 
order for them to receive the best treatment possible.  
 
92  See id. 
93  Id. 
94  See 42 C.F.R. § 2.14(a) (2018). 
95  See supra notes 86, 90. 
96  Supra Part II.C. 
97  Michael Dahr, Is the Teen Brain More Vulnerable to Addiction?, HUFFPOST (Jan. 21, 2014), 
https://www.huffpost.com/entry/teen-brain-addiction-vulnerable_n_4638723. 
98  Id. 
99  Id. 
100  Todd Finley, Your Face Scares Me: Understanding the Hyperrational Adolescent Brain, 
EDUTOPIA (June 10, 2014), https://www.edutopia.org/blog/understanding-the-hyperrational-
adolescent-brain-todd-finley. 
101  See id. 
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A. Medical Informed Consent 
Along with capacity, informed consent is important within the medical 
decision-making process. There are four elements that must be met for informed 
consent: (1) the person must have the capacity to make the decision; (2) the provider 
must disclose all information, including the likelihood of benefits and risks; (3) the 
information must be understood; and (4) the patient must voluntarily consent.102 
Providers must tell patients the material information a reasonable person would 
need to make an intelligent decision.103 Disclosure includes the likelihood of the 
risks and the benefits, side effects, and alternatives to whatever procedure or 
treatment option is discussed.104 Informed consent is vital to patient autonomy, 
allowing patients to make their own medical decisions.105 Further, informed consent 
must be obtained before patients’ medical information can be released. 
B. Medical Capacity and Providers’ Ethical Duties 
When caring for patients, physicians rely on four elements to assess 
capacity.106 Patients must have: (1) understanding of relevant information about 
proposed diagnostic treatment; (2) appreciation for their situation; (3) reasoning 
used to make decisions; and (4) the ability to communicate their choice.107 Medical 
scholars have noted that, where patients’ capacity is in question, other experts like 
psychiatrists should be used.108 
The American Medical Association (AMA) Code of Medical Ethics provides 
further guidance on challenging ethical questions that many providers face when 
dealing with their patients, the law, and their morals.109 The Opinion, “Confidential 
Care for Minors,”110 states that minors should be involved in the medical decision 
process to the extent that their abilities allow.111 Providers are encouraged to give 
minors as much autonomy as possible so minors feel in control of their treatment; 
 
102  Richard A. Wagner, Informed Consent, EMEDICINE HEALTH (Oct. 17, 2018), 
https://www.emedicinehealth.com/informed_consent/article_em.htm#what_is_informed_consent. 
103  Id. 
104  Id. 
105  Id. 
106  Assessing Medical Decision-Making Capacity, PHYSICIANS WEEKLY (May 8, 2012), 
https://www.physiciansweekly.com/medical-decision-making-capacity/. 
107  Id. 
108  Joyeeta G. Dastidar & Andy Odden, How Do I Determine if My Patient Has Decision-Making 
Capacity?, THE HOSPITALIST (Aug. 2011), https://www.the-hospitalist.org/hospitalist/article/ 
124731/how-do-i-determine-if-my-patient-has-decision-making-capacity. 
109  See AMA CODE OF MEDICAL ETHICS, https://www.ama-assn.org/delivering-care/ama-code-
medical-ethics (last updated 2018). 
110  Opinion 5.055-Confidential Care for Minors, AM. MED. ASS’N J. ETHICS (Nov. 2014), 
https://journalofethics.ama-assn.org/article/ama-code-medical-ethics-opinion-adolescent-
care/2014-11. 
111  Id. 
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however, physicians should also encourage parental involvement.112 The Opinion 
notes that, especially regarding substance and alcohol use, “when the physician 
believes that, without parental involvement and guidance, the minor will face a 
serious health threat, and there is reason to believe that the parents will be helpful 
and understanding, disclosing the problem to the parents is ethically justified.”113 
Before disclosure, the breach of confidentiality must be discussed with the minor 
patient, and at times, the AMA supports following the child’s disclosure wishes.114  
C. Legal Capacity 
Legal capacity comes into question in many decision-making circumstances. 
To determine capacity, courts look at one’s ability to reason, deliberate, hold both 
values and goals, appreciate circumstances, understand information, and 
communicate a choice.115 Capacity may change over time; therefore, repeated 
assessments of capacity may be necessary.116 One perspective courts use is that 
capacity is a balancing act examining how much autonomy a person possesses and 
how much value lies in respecting the autonomy.117 Generally, the higher a person’s 
level of capacity, the more that person’s autonomy will be respected.118 Adolescents’ 
ability to deliberate or reason may be diminished by immaturity, poor 
understanding of actions and consequences, and SUD’s effect on the brain.119 For 
example, adolescents may overestimate the threat of telling parents about their 
SUD. 
D. Traditional Legal Treatment of Minors in Health Decisions 
The legal system has traditionally viewed children and teens as a vulnerable 
group, subject to extra protections.120 The Supreme Court has articulated that “[o]ur 
history is replete with laws and judicial recognition that minors . . . generally are 
less mature and responsible than adults. Particularly ‘during the formative years of 
childhood and adolescence, minors often lack the experience, perspective, and 
judgment’ expected of adults.”121 The legal system assumes that adults are 
 
112  Id. 
113  Id. 
114  Id.  
115  Alec Buchanan, Mental Capacity, Legal Competence and Consent to Treatment, 97 J. ROYAL 
SOC’Y MED. 415, 415 (2004). 
116  Id. 
117  Id. at 416. 
118  Id. 
119  See supra Part II.C. 
120  See What are the Legal Rights of Children?, FINDLAW.COM, 
https://family.findlaw.com/emancipation-of-minors/what-are-the-legal-rights-of-children.html 
(last visited Oct. 17, 2018) (showing the amount of laws put in place to protect children). 
121  Thompson v. Oklahoma, 487 U.S. 815, 834 (1988) (quoting Bellotti v. Baird, 443 U.S. 622, 635 
(1979)). 
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competent, but children often must prove that they are competent.122 While 
research shows that some children demonstrate adult competence around the age of 
fourteen, this depends on the situation and the complexity of the issues that the 
minor faces.123 Thus, minors who make decisions often deserve protection according 
to the law. 
Courts have historically distinguished children and adults124 because 
children are psychologically more vulnerable to external influences.125 In Bellotti v. 
Baird, the Supreme Court ultimately decided that, although minors did not need 
parental approval for abortions, their autonomy and ability to seek treatment 
cannot be the same as adults because of vulnerability, their inability to make 
mature, informed decisions, and the importance of parents’ role in raising their 
children.126 The Supreme Court found that, while the child did not need parental 
approval before obtaining an abortion, children still represent a protected class due 
in part to their vulnerability.127 Bellotti v. Baird gives children extra protections 
even if parents are not involved in the initial medical decision-making process.128 
Based on precedent, extra protections should be afforded to adolescents seeking 
SUD treatment. The protections should manifest in the way that adolescents are 
being informed of their treatment options because not only do adolescents generally 
lack maturity, but, in these cases, they also suffer from the deficit of the SUD. 
The Supreme Court again noted the seriousness of children’s medical 
decisions prompting stigma. In Parham v. J.R., concerning a child’s involuntary 
institutionalization because of mental illness, the Court noted the importance of 
determining whether institutionalization was necessary because it was 
stigmatizing;129 therefore, it was decided that other professionals should confirm 
treatment needs besides simply relying on the decision of the parents.130 Courts will 
insert themselves into familial relationships to protect children’s interests only in 
the most serious cases,131 because “parents can and usually do play a significant 
role in the treatment . . . [and] there is a serious risk that an adversary 
confrontation will adversely affect the ability of the parents to assist the child.”132 
 
122  Richard E. Redding, Children’s Competence to Provide Informed Consent for Mental Health 
Treatment, 50 WASH. & LEE L. REV. 695, 743–44 (1993) (introducing framework that would still 
presume incompetence to protect the rights and interests of the child). 
123  Id. at 725, 727. 
124  Thompson v. Oklahoma, 487 U.S. at 823 (prohibiting the execution of a person who was sixteen 
years old at the time of the committed murder). 
125  Id. at 834 (quoting Eddings v. Oklahoma, 455 U.S. 104, 115–16 (1982)). 
126  443 U.S. 622, 633–34 (1979) (finding mature minors can go to the court to receive court consent 
for the minor to receive an abortion). 
127  Id. 
128  Id. at 643–44. 
129  Parham v. J.R., 442 U.S. 584, 600–01 (1979). 
130  Id. at 606–07. 
131  See id. at 610. 
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2020] Protecting Minors with Substance Use Disorders 415 
 
While courts will interfere with children’s medical decisions made by parents, 
courts interference will clearly be in very limited and stigmatizing circumstances. 
Not all advocates agree with the precedent of protecting minors and 
questioning their decision-making abilities, but instead see children’s legal and 
societal lack of decision-making ability as an affront to their dignity.133 Some 
believe that children are “the most oppressed of all the minorities” because they are 
unable to make their own life decisions.134 Children’s rights advocates note that in 
order for children to not be mistreated, they should always receive a say in the 
decisions affecting their lives.135 Many feel that as children possess a voice 
regarding their life decisions they are then provided with a higher level of 
autonomy.136 
However, similar to the Supreme Court noting that parents may “play a 
significant role in treatment,” parental involvement should be encouraged in most 
forms of SUD treatment.137 The confidentiality in Section 2.14 for minors may place 
a chilling effect on both providers encouraging parental involvement in treatment, 
and adolescents fully understanding the benefits which they are closing themselves 
off from with confidentiality. 
IV. ISSUES OF CONFIDENTIALITY AND MINOR PATIENTS WITHIN SECTION 2.14(C) 
There are times when providers may breach confidentiality because 
significant harm may arise from not reporting SUD treatment.138 It is important to 
note that adolescents have the capacity to enter into the initial SUD treatment, 
therefore initial capacity should not be considered.139 Based on Section 2.14(c), there 
are a few situations where treatment providers can break confidentiality.140 Section 
(c) of “Minor patients” articulates that confidentiality for the minor can be broken if 
the minor:  
lacks capacity for rational choice. Facts relevant to reducing a 
substantial threat to the life or physical well-being of the minor 
applicant . . . may be disclosed to the parent . . . or other individual 
authorized under state law to act in the minor's behalf if the part 2 
program director judges that: (1) A minor applicant for services lacks 
capacity because of extreme youth[ ](sic.) or mental or physical 
condition to make a rational decision on whether to consent to a 
disclosure . . . to their parent . . . or other individual authorized under 
 
133  See Redding, supra note 122, at 704. 
134  Id. (quoting THE CHILDREN’S RIGHTS MOVEMENT: OVERCOMING THE OPPRESSION OF YOUNG 
PEOPLE 1 (Beatrice Gross & Ronald Gross eds., 1977)). 
135  Id. 
136  See id. 
137  Parham v. J.R., 442 U.S. 584, 610 (1979). 
138  42 C.F.R. § 2.14(c) (2018). 
139  See id. 
140  Id. 
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state law to act in the minor's behalf; and (2) The minor applicant's 
situation poses a substantial threat to the life or physical well-being of 
the minor applicant . . . which may be reduced by communicating 
relevant facts to the minor's parent . . . or other individual authorized 
under state law to act in the minor's behalf.141 
Similar to the public’s comments about the vagueness of the regulation,142 more 
guidance should be given to treatment providers on how to assess the adolescent’s 
maturity or ability to make a “rational choice.” Treatment providers should also be 
given better guidelines to understand the “substantial threat[s]” that can be caused 
by SUD. Analysis of section (c) is necessary to understand where additions and 
clarifications are needed within the regulation. 
A. Minors Lacking Maturity Based on Psychological Studies and Supreme Court 
Precedent within Section 2.14(c)(1)  
Most adolescents have the initial level of capacity to receive SUD treatment; 
however, the mental state of adolescents should be taken into consideration and 
continually reassessed, especially for confidentiality within substance use 
treatments.143 Considering subsection (1) of Section 2.14(c), regarding mental 
conditions affecting an adolescent’s ability to make a “rational decision,” treatment 
providers should be considering what type of substance the youth has been using 
and how long use has occurred.144 This would include issues like heavy drinking, 
which is known to cause problems with the working memory,145 and regular 
marijuana use, which causes problems with decision-making ability.146  
When examining the substantially precarious mental state of children with 
SUD, it is important to consider that they have a decision-making deficit that stems 
from the implications of substance use on the growing brain, along with 
immaturity.147 While the core issue is not a “mental . . . condition,”148 there is 
instead a lack of understanding and appreciation that continued confidentiality may 
be problematic for their treatment. While inclusion of adolescents in decision-
making proves important for development and trust,149 there may be times, based 
on psychological states, that they lack the maturity to fully make decisions. 
Further, involving adolescents in the decision-making process does not negate the 
 
141  Id. (emphasis added). 
142  Supra notes 44–45 and accompanying text. 
143  See Buchanan, supra note 115, at 415. 
144  42 C.F.R. § 2.14(c)(1) (2018). 
145  Bava & Tapert, supra note 76, at 405. 
146  Squeglia et al., supra note 72, at 3. 
147  See supra Part II.C. 
148  42 C.F.R. § 2.14(c)(1) (2018). 
149  See COMM’R FOR CHILDREN, INVOLVING CHILDREN IN DECISION MAKING (2015) (including children 
in the decision-making process has many developmental benefits). 
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fact that most parents should, at most times, be aware of what happens in their 
children’s lives, especially with SUD treatment decisions.150 
B. Substantial Threat to the Well-being of Minors Under Section 2.14(c)(2) 
Confidentiality of minors within a substance use treatment program may also 
be broken if “[t]he minor applicant's situation poses a substantial threat to the life 
or physical well-being of the minor applicant . . . which may be reduced by 
communicating relevant facts to the minor's parent.”151 The substantial threat 
would most likely come from the type and amount of the substances the adolescent 
uses.152 Adolescents using opioids should most likely be reported to parents or 
guardians due to the serious and substantive information that has been gathered 
surrounding the opioid epidemic and its serious effects on adolescents; for example, 
55% of child opioid deaths in a poison control study were teenagers.153 Parents 
should also be notified when certain lethal combinations of substances are used. 
Not only should treatment providers look at the type and frequency of 
substance use, but the providers must also balance the seriousness of the 
adolescent’s issues with the risks or benefits of parental involvement. Family-based 
treatments can be more effective than individual and group treatment 
approaches.154 Including parents and family in SUD treatment allows children to 
improve communication skills and work on conflict resolution within the family,155 
helping to identify and manage any underlying problems related to the substance 
use and may also allow parents to be supportive.156 Parents can schedule 
appointments and “provid[e] needed structure and supervision through household 
rules and monitoring.”157 Family involvement should be part of the SUD treatment 
package. Treatment providers have a duty to inform minors of the benefits of family 
inclusion under the “best interests of the patient” because this is an established 
treatment option.158 
 
150  See NAT’L INST. ON DRUG ABUSE, supra note 86, at 17. 
151  42 C.F.R. § 2.14(c)(2) (2018). 
152  SALLY C. CURTIN, BETZAIDA TEJADA-VERA & MARGARET WARNER, NAT’L CTR. FOR HEALTH STATS., 
DATA BRIEF NO. 282, DRUG OVERDOSE DEATHS AMONG ADOLESCENTS AGED 15–19 IN THE UNITED 
STATES: 1999–2015, at 1 (2017), https://www.cdc.gov/nchs/products/databriefs/db282.htm (“The 
death rate due to drug overdose among adolescents aged 15–19 more than doubled from 1999 
(1.6 per 100,000) to 2007 (4.2), declined by 26% from 2007 to 2014 (3.1), and then increased in 
2015 (3.7).”). 
153  Norton, supra note 66 (studying calls to U.S. poison control centers for help with children or 
teens who had ingested prescription opioids). 
154  NAT’L INST. ON DRUG ABUSE, supra note 86, at 25–26. 
155  Boldt, supra note 73, at 109–10. 
156  Id. at 110. 
157  NAT’L INST. ON DRUG ABUSE, supra note 86, at 117. 
158  Opinion 5.055-Confidential Care for Minors, supra note 110 (“[W]hen the physician believes that, 
without parental involvement and guidance, the minor will face a serious health threat, and 
there is reason to believe that the parents will be helpful and understanding, disclosing the 
problem to the parents is ethically justified.”). 
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While family-based treatments have been found to be beneficial to 
adolescents, in some cases, involving parents in SUD treatment could jeopardize 
success. Adolescents could be further harmed if their SUD comes from a 
dysfunctional family relationship or from inappropriate or harmful relationships 
with parents.159 However, the National Institute on Drug Abuse noted that some 
therapy combinations of family-based treatment and individual treatment can be 
very beneficial for adolescents because they allow children to confront parents and 
identify issues in a healthy setting.160 These treatments work to improve 
“communication, problem-solving, conflict resolution, and parenting skills.”161 
Further, studies have found that simply having social support aids in the treatment 
process.162 The information on the substantial benefits of the family-based 
treatment, depending on the nature of the problem of the adolescent’s substance 
use, may outweigh the benefits of confidentiality. 
V. PROPOSED SOLUTION TO THE VAGUENESS OF 42 CFR 2.14(C) 
Section 2.14 of the regulation should be further updated to include more 
specific guidelines for minors and confidentiality.163 Adolescents have the capacity 
to seek treatment, but once they do, they then need the social support to make good 
decisions in the future.164 Removal of confidentiality may benefit future decision 
making. Updates should focus on adolescents making a “rational decision” by 
receiving full information from providers about the benefits of family-based 
treatment. Within Section 2.14 there should be full disclosure by providers about 
the benefits and risks of social support and family-based treatment. Also, there 
should be a clearer exception with Section 2.14(c), allowing confidentiality to be 
broken if assessments determine that the adolescent would benefit. The updates 
should also focus on providing guidelines so providers can accurately assess, within 
Section 2.14(c), if there is “substantial threat or harm” to the adolescent. 
Under this updated system, initial confidentiality should apply until 
assessment is complete because there are risks that minors will not seek the 
treatment both that they need and are willing to receive if confidentiality cannot be 
guaranteed.165 While some minors will not seek SUD treatment based on the 
possibility that it will be disclosed to their parents or guardians, the initial 
confidentiality between the treatment providers and adolescents will build trust 
 
159  Boldt, supra note 73, at 110. 
160  See NAT’L INST. ON DRUG ABUSE, supra note 86, at 26 (looking at not only the adolescent’s 
problems, but also at problems like parental substance use). 
161  Id. 
162  Sharon M. Kelly, Kevin E. O'Grady, Robert P. Schwartz, James A. Peterson, Monique E. Wilson 
& Barry S. Brown, The Relationship of Social Support to Treatment Entry and Engagement: The 
Community Assessment Inventory, PUBMED CENT. 1, 6–7 (2011). 
163  42 C.F.R. § 2.14 (2018). 
164  Recovery and Recovery Support, supra note 90. 
165  See supra Part II.A. 
2020] Protecting Minors with Substance Use Disorders 419 
 
with those adolescents who do seek help.166 The trust will allow minors to have 
more open and honest conversations with their treatment providers, and hopefully 
encourage them to accept treatment providers’ advice.167 Similar to the AMA Code 
of Medical Ethics guidance for minors’ confidentiality, patients’ opinions must be 
considered to promote autonomy; however, if a provider feels that the minor’s 
parents should be informed, the provider must discuss this with the minor prior to 
disclosure, even if Section 2.14 exceptions are met.168 Conversations built from a 
trusting relationship can open channels of communication between the provider and 
minor, which ultimately will promote the minor’s wellbeing.169 
The updated regulation will allow for more structure as to when providers 
can disclose SUD treatment. This proposed plan accords with the purposes 
underlying Section 2.14: not interfering with the parent-child relationship and 
giving providers freedom to protect minors from possibly harmful situations.170  
A. Providing Adolescents Information Necessary for Informed Consent: The 
Possible Benefits and Risks of Family-Based Treatment 
In order to truly give informed consent, minors must be provided information 
about all of the risks and benefits of family-based treatment, and they must fully 
understand how confidentiality ties into the obstruction of these possible benefits. 
While there is not an extensive body of research, studies have found that family-
based treatment is more effective than other treatments that do not use family-
based approaches.171 The information about the benefits of family-based treatment 
should be explained to adolescents, and providers should make sure to confirm that 
the adolescents fully understand this information. Providers should also give 
information about the importance of social support benefits, encouraging 
adolescents to allow information to be shared with a trusted adult if their parents 
are unavailable or would not be helpful. If providers are able, they should also try to 
 
166  See Maria Allinson & Betty Chaar, How to Build and Maintain Trust with Patients, 
PHARMACEUTICAL J. (Nov. 16, 2016), https://www.pharmaceutical-journal.com/pharmacy-
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170  Part 2—Confidentiality of Alcohol and Drug Abuse Patient Records, 40 Fed. Reg. 27802, 27808 
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have a conversation with parents to better determine the parents’ involvement in 
the adolescent’s life and their understanding of the child’s substance use.172 
The updated regulation would then continue with the inclusion of a mental 
health professional. If a minor still refused family-based treatment, a 
psychologist173 would need to see the minor to determine if the minor would benefit 
from family-based treatment. The psychologist would then be required to document 
that family-based treatment would not be helpful in order to completely solidify the 
confidentiality. The family-based treatment may not be beneficial if the minor 
struggles from a precarious home-life and informing the parents would only 
exacerbate the situation.174 However, psychologists will note times when family-
based treatment can help adolescents with problems at home, because the 
treatment will address those underlying problems.175  
Further, the approach would comport with the AMA Code of Medical Ethics, 
where if a provider believes that “parents will be helpful and understanding,” the 
information about the substance use treatment should be disclosed.176 This 
guidance will ensure that minors are being given more information about the 
benefits of parental involvement in their SUD treatment. The approach will 
emphasize that for true informed consent to exist, minors must understand the 
possible benefits that they are giving up in choosing confidentiality.  
B. Accessing the Risk for Substantial Harm: The Psychological Effects of the 
Amount and the Type of Substance Use 
In entering SUD treatment, minors recognize that the substance use is a 
problem in their lives, but treatment providers still must identify the problem’s 
extent. In the updated framework of the regulation, treatment providers should 
identify the length and frequency of the minor’s substance use. Based on studies 
illustrating the detriments to an adolescent’s brain due to substance use, the 
treatment provider would have to assess whether the SUD limits the minor’s 
decision-making ability or affects the adolescent’s brain after the minor’s initial 
decision to receive treatment. 177 The assessment would occur not only through 
tests, SUD treatment providers also would be presented with a detailed guideline 
that defines what drugs should be flagged for possibly categorizing a child as high 
risk. The determination of a high risk child would be defined from the regulation as 
a child whose SUD combination or use possesses a “substantial threat to the life or 
physical well-being of the minor applicant.”178 These guidelines would give SUD 
 
172  See supra Part II.C. (explaining that providers should attempt to interview parent-like figures in 
the adolescents’ lives if they do not have substantial biological parent contact). 
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providers more clarity on what high risk looks like or those substances that can 
substantially affect the brain, leading to swift and serious outcomes. 
Providers would next identify whether the minor has the level of maturity to 
properly understand confidentiality. This would also be based on the information 
that was previously disclosed about the importance of social support systems and 
family-based treatment. The minor would need to show the ability to understand 
and appreciate the situation.179 In these cases, the minor would need to be informed 
of the risks and benefits of the treatment without including the parents.180 Minors 
would demonstrate their maturity not only through the meeting with the provider 
but also through several different types of assessments. The assessments would be 
administered through counseling to make sure that they understand the benefits of 
social support and family-treatment. The assessment would further test their level 
of maturity and understanding of the idea of confidentiality and the positives, along 
with negatives, of not including parents in treatment. The meetings with the 
provider, paired with the examinations, would ensure that minors fully understand 
the constraints of confidentiality in relation to their treatment. 
These additions to the regulation would protect adolescents who are at high 
risk from falling through the cracks of the system or the regulation. Furthermore, it 
would ensure that adolescents are fully informed that the benefits of social support 
and parental involvement generally outweigh the “risks” of informing parents. 
CONCLUSION 
 Adolescents have been treated as a vulnerable population, subject to extra 
protections, within society and the law. Adolescents with SUD may be in a 
heightened state of vulnerability because of their lack of maturity, compounded 
with the neurological deficits caused by SUD. Research has found that 
environmental factors play a large role in the treatment and recovery of adolescents 
suffering from SUD.181 These treatment options can range from group therapies to 
family-based treatments.182 The benefits of treatment may then come into conflict 
with Section 2.14, which has the main purpose of allowing minors to consent to 
confidentiality within SUD treatment. 
 When enacted in 1975, Part 2 served the goal of allowing people, including 
minors, to confidentially receive treatment for SUD without the stigma.183 Based on 
the current knowledge of the effects of SUD on adolescents’ brains and the 
importance of social support, including family-based treatment, Section 2.14 should 
be updated to provide clear treatment reasons as to when disclosure of SUD 
treatment is necessary. The updates should include full disclosure to adolescents of 
 
179  Assessing Medical Decision-Making Capacity, supra note 105. 
180  See NAT’L INST. ON DRUG ABUSE, supra note 85, at 30 (showing the benefits of including parents 
in treatment options). 
181  See supra notes 85–88 and accompanying text. 
182  See NAT’L INST. ON DRUG ABUSE, supra note 85, at 23. 
183  Part 2—Confidentiality of Alcohol and Drug Abuse Patient Records, 40 Fed. Reg. 27,802; 42 
C.F.R. § 2.14 (2018). 
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the benefits of family-based treatment, ensuring that adolescents fully understand 
and consider these benefits, and distinct guidelines for treatment providers to 
report SUD treatment to parents based on possible harm.  
Ultimately, while the implications of the social stigma should be considered 
when treating adolescents with SUD, the social support may not only benefit 
adolescents, but may be necessary throughout minors’ treatments. The purpose of 
Section 2.14 is to allow minors to seek the treatment that they need; therefore, it is 
vital that the regulation does not produce a chilling effect on the treatment, making 
providers hesitant to advocate against confidentiality and for family-based 
treatment. While the confidentiality and autonomy provided by Section 2.14 prove 
important, adolescents still maturing and dealing with the effects of SUD must be 
fully informed about how the benefits of family-based treatment may outweigh any 
risks that may concern them. In conclusion, the full disclosure of the benefits of 
SUD family-based treatments will allow adolescents to give informed consent, 
promoting autonomy, while still working to protect and treat these vulnerable 
adolescents. 
